SPDR Gold Trust vs Hims and Hers Health Inc — how do they compare? SPDR Gold Trust trades at $383.66 (market cap $139.66B), while Hims and Hers Health Inc trades at $28.41 (market cap $6.55B). The key difference: SPDR Gold Trust is far larger — about 21.3× Hims and Hers Health Inc's market cap, and Hims and Hers Health Inc is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SPDR Gold Trust for 74 Days and Hims and Hers Health Inc for 21 Days on average.
| GLD | HIMS | |
|---|---|---|
Market Cap | $139.66B | $6.55B |
Volume | 9,544,773 | 14,842,814 |
52-Week High | $495.90 | $62.76 |
52-Week Low | $362.32 | $14.52 |
Typical Hold Time | 74 Days | 21 Days |
Sector | — | Health |
Enterprise Value | — | $7.25B |
Signals from Pluang's Aura AI — not financial advice
GLD is trading at $375.88, down 1.66% over the past 24 hours amid broader market pressure from rising Treasury yields and Federal Reserve policy uncertainty. The technical picture remains bearish with moving averages and oscillators signaling continued downward momentum, while key support levels cluster around $372-375. Recent news highlights gold's struggle to maintain gains despite weak economic data, with prices testing critical support zones.
The outlook for GLD remains challenged by persistent headwinds from elevated yields and dollar strength, though some analysts see tactical buying opportunities at current levels. Key risks include further Fed tightening and deteriorating technical momentum, while potential catalysts include sustained inflation concerns and geopolitical tensions that could revive safe-haven demand.
Hims & Hers Health trades at $29.54, up slightly by 0.24% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported revenue of $2.35 billion in 2025 but swung to a net loss of $142 million in 2026, with a negative net margin of 5.51%. Analyst consensus is a 'Hold' with a price target of $32.17, but the stock faces significant headwinds from multiple securities class action lawsuits announced in early October 2026.
The outlook for HIMS is clouded by legal risks and profitability challenges despite revenue growth. Investment opportunity hinges on the company's ability to return to profitability and resolve regulatory scrutiny. Key risks include ongoing litigation, FTC complaints, and execution missteps in a competitive telehealth market. Wall Street remains cautious with 65% of analysts recommending Hold.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →